LAG3 and diffuse large B-cell lymphoma: Hence, dysregulated LAG-3 expression has been reported to negatively correlate with clinical outcome in a wide variety of cancers, including some of hematological origin, including CLL, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or acute myeloid leukemia (AML) [20,21,22].